$FMS

Fresenius Medical Care (FMS) is accelerating the U.S. rollout of its 5008X CAREsystem, with 227 clinics converted by July 2026. Early clinical evidence shows benefits, but earnings impact may take time due to near-term constraints like weak treatment volumes and reimbursement changes. The company faces rollout costs and headwinds from TDAPA reimbursement, with full-year 2026 drag estimated at €50 million.

Fresenius Medical Care AG repurchased 733,131 shares from August 24-28, 2026, part of a larger tranche starting May 28, 2026. The company has acquired 6,589,405 shares in total under this program. A credit institution handles the purchases, and the company will provide regular updates.

Fresenius Medical Care AG reported that BlackRock, Inc. crossed the 5% voting rights threshold, holding 6.63% as of August 25, 2026. This includes 5.13% from shares and 1.50% from financial instruments. The disclosure follows German Securities Trading Act requirements.

Fresenius Medical Care recalled 1,140 hemodialysis machines (models 191126 and 191130) due to flow, no-water, and temperature alarms. The FDA classified it as Class II, indicating temporary or reversible harm. Clinics must use backup machines until parts are replaced, potentially disrupting schedules.

Fresenius Medical Care AG repurchased 705,000 shares from August 17 to 21, 2026, as part of its first tranche of a share buyback program. The company has acquired a total of 5,856,274 shares in this tranche. The buyback is being executed by a commissioned credit institution. Regular updates will be posted on the company's investor relations page.

Fresenius Medical Care AG reported interim results of its first tranche share buyback. From Aug 10 to Aug 14, 2026, it bought back 722,500 shares at weighted average prices around EUR 41.06 to EUR 42.36, totaling EUR 30.65m. A total of 5,151,274 shares have been acquired so far, via a commissioned credit institution.

Fresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 5% organically, and adjusted operating income of EUR 569 million (+23% at constant currency). Adjusted basic EPS was EUR 1.13 (+28% constant currency). Management reaffirmed broadly flat 2026 revenue and operating income growth, citing U.S. referral execution issues and China regulatory headwinds.

Germany’s DAX rose modestly in Thursday morning trading, reaching 26,210.50 before easing to 26,169.49 (+0.12%). Deutsche Telekom gained about 6% on Q2 operating profit of €6.863bn and a larger 2026 buyback. Merck rose 1.5% after upgrading full-year guidance. Other moves included Henkel (+4.3%) and Siemens (-6%).

European stocks closed higher on Tuesday. The pan-European Stoxx 600 rose 0.73%, with DAX up 0.77% and CAC 40 up 0.61%. Brent crude fell nearly 6% to $78.70. Company moves included Travis Perkins +18.5% on strong interim results, Smith & Nephew -6% after cutting its forecast, and Zalando -13.4% after lowering its 2026 outlook. HSBC reported $14.626B net income and announced a share buyback.

Fresenius Medical Care (NYSE:FMS) reported Q2 call highlights, including clinic closures of about 100 underperforming sites and rollout of high-volume hemodiafiltration. The company said U.S. same-market treatment growth for 2026 should stay around Q2 levels due to lower referrals. Care Delivery operating income rose 45% and FCF was EUR 625 million. It expects TDAPA to be a EUR 50 million full-year headwind and is buying back shares under a EUR 1 billion program.